Literature DB >> 10852623

Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

R Schvarcz1, G Rudbeck, G Söderdahl, L Ståhle.   

Abstract

A 49-year old male patient with severe hemophilia A, coinfected with HIV and HCV, who underwent orthoptic liver transplantation because of hepatitis C cirrhosis is presented. We describe a strong interaction between nelfinavir and tacrolimus postoperatively, that caused a reduction of the dose of tacrolimus by a factor 70 compared with normal, to achieve therapeutic blood concentrations and to avoid toxic side effects. We suggest that nelfinavir inhibits the metabolism of tacrolimus because both compounds are well-known substrates for the cytochrome P450 isoenzyme CYP 3A4. The nelfinavir serum concentrations were not affected by the institution of tacrolimus. Although the interaction dramatically changed the tacrolimus dose-concentration relationship, the situation was manageable by frequent monitoring of blood concentrations of tacrolimus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852623     DOI: 10.1097/00007890-200005270-00041

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report.

Authors:  Gaëlle Hardy; Françoise Stanke-Labesque; Claudine Contamin; Françoise Serre-Debeauvais; François Bayle; Philippe Zaoui; Germain Bessard
Journal:  Eur J Clin Pharmacol       Date:  2004-09-15       Impact factor: 2.953

Review 3.  Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years.

Authors:  G Hütter; J A Zaia
Journal:  Clin Exp Immunol       Date:  2011-03       Impact factor: 4.330

4.  The treatment choices and outcome of hepatocellular carcinoma in hemophilic patients with human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfection due to contaminated blood products in Japan.

Authors:  Mitsuhisa Takatsuki; Koji Natsuda; Masaaki Hidaka; Koji Sawada; Motohiro Shindo; Tomoyuki Endo; Takeshi Hagiwara; Hiroshi Yotsuyanagi; Tomohiko Koibuchi; Kunihisa Tsukada; Haruka Uemura; Kazuhiko Hayashi; Tomoko Uehira; Eiji Mita; Masahiro Yamamoto; Soichiro Takahama; Susumu Eguchi
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 5.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

Authors:  Elina Teicher; Isabelle Vincent; Laurence Bonhomme-Faivre; Chadi Abbara; Aurélie Barrail; Alain Boissonnas; Jean-Charles Duclos-Vallée; Anne-Marie Taburet; Didier Samuel; Daniel Vittecoq
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Liver transplantation().

Authors:  M Rossi; G Mennini; Q Lai; S Ginanni Corradini; F M Drudi; F Pugliese; P B Berloco
Journal:  J Ultrasound       Date:  2007-04-16

8.  Liver transplant in patients with HIV: infection risk associated with HIV and post-transplant immunosuppression.

Authors:  Pierluigi Viale; Umberto Baccarani; Marcello Tavio
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

Review 9.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Authors:  Dirk R J Kuypers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.